Systemic Lupus Erythematosus

SYSTEMIC LUPUS ERYTHEMATOSUS

Hydroxychloroquine Does Not Increase Risk for Arrhythmia in Patients With SLE and RA

Researchers evaluated the link between hydroxychloroquine use and corrected QT length in patients with SLE and RA without cardiovascular disease.
Patients With SLE Can Have Low Immune Response to COVID-19 Vaccines

Nearly one-third of systemic lupus erythematosus (SLE) patients have a low response to the COVID-19 vaccine.
Specificity of anti-dsDNA Immunoassays in Systemic Lupus Erythematosus

The specificity of fluorescence immunoassays for anti–dsDNA was ≥90% in this meta-analysis of studies including patients with SLE.
Short-Term COVID-19 Outcomes Worse in SLE, Lupus Nephritis

Patients with lupus nephritis should be allow early access to COVID-19 vaccination, according to investigators.
Nephrologists and Rheumatologists View Lupus Nephritis Treatment Options Differently

In a survey, more rheumatologists than nephrologists viewed belimumab and voclosporin as a “substantial advance” in lupus nephritis treatment.
Belimumab Effective in Relapsed and Newly Diagnosed Lupus Nephritis

Standard therapy for lupus nephritis achieves complete renal response in only 20% to 40% of patients.
Voclosporin Demonstrates Efficacy in Severe Lupus Nephritis

Voclosporin acts as an anti-inflammatory agent and also stabilizes podocytes to reduce proteinuria.
ACR 2021 Debate: Enhancing Standard Lupus Nephritis Therapy With Belimumab or Voclosporin

At this year’s ACR Convergence Great Debate, Michelle Petri, MD, MPH, and Brad Rovin, MD, discuss their preferred choice of add-on drug – belimumab or voclosporin – to standard lupus nephritis therapy.
Gaps in Contraception Documentation for Women With SLE and RA in ACR’s RISE Registry

Researchers assessed the frequency of contraception documentation for women with systemic lupus erythematosus and rheumatoid arthritis in the ACR’s RISE registry.
Belimumab Promising in Combination Therapy for Refractory Lupus

Patients were treated with rituximab and then randomly assigned four to eight weeks later to receive intravenous belimumab or placebo for 52 weeks.

LATEST NEWS

Systemic Lupus Erythematosus Increases MACE Risk After Noncardiac Surgery

In research presented at the ACR Convergence 2021, investigators estimated the risk of major adverse cardiac events in patients with systemic lupus erythematosus undergoing moderate-risk to high-risk surgery.

Belimumab May Reduce Glucocorticoid Use in Systemic Lupus Erythematosus

A team of investigators assessed the speed with which patients with systemic lupus erythematosus decreased their use of glucocorticoids following treatment with belimumab vs placebo.

Novel Biomarker May Predict Development of Lupus Enteritis in Patients With Systemic Lupus Erythematosus

Researchers compared the clinical manifestation of patients with systemic lupus erythematosus with the anti-gAChR antibody.

Higher Prevalence of SLE in Patients With Myasthenia Gravis

Researchers assessed the prevalence of SLE among patients with vs without myasthenia gravis (MG), and studied the demographics of patients with MG who developed SLE after their MG diagnosis.

A man pouring out many tablets from a prescription bottle

Anifrolumab Beneficial Among Patients With SLE, Regardless of Prior Biologics Use

Researchers used pooled data from the TULIP-1 and TULIP-2 trials to assess the effect of prior biologics use on anifrolumab efficacy and safety in systemic lupus erythematosus.

Predictors of Remission and Low Disease Activity Assessed in Systemic Lupus Erythematosus

Researchers assessed the predictors of remission and lupus low disease activity state (LLDAS) in patients with systemic lupus erythematosus.

Distinct Differences in Brain Functional Connectivity Among Patients With and Without Cognitive Impairment in SLE

Researchers studied the association between functional connectivity, permeability of the blood-brain barrier, and cognitive impairment in patients with systemic lupus erythematosus.

Worsening Disparities in Lupus Nephritis Mortality by Race, Urbanization

Researchers analyzed mortality trends in lupus nephritis in the US from 1999 to 2019 and identified population characteristics associated with mortality.

Hydroxychloroquine Maintenance Associated With Lower Flare Risk in Patients With SLE

Researchers assessed the association between disease activity status and SLE flare risk after hydroxychloroquine reduction or discontinuation vs maintenance.

Sustained Proteinuria Reductions With Voclosporin in Patients With Lupus Nephritis

In a second interim analysis of the AURORA 2 extension study, researchers reported on the effects of voclosporin on lupus nephritis.

Next post in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

LATEST NEWS

Want to read more?